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Abstract
Background: Little is known about treatment of multidrug-resistant tuberculosis (MDR-TB) in high HIV-prevalence settings
such as sub-Saharan Africa.
Methodology/Principal Findings: We did a retrospective analysis of early outcomes of the first cohort of patients registered
in the Lesotho national MDR-TB program between July 21, 2007 and April 21, 2008. Seventy-six patients were included for
analysis. Patient follow-up ended when an outcome was recorded, or on October 21, 2008 for those still on treatment. Fifty-
six patients (74%) were infected with HIV; the median CD4 cell count was 184 cells/ml (range 5–824 cells/ml). By the end of
the follow-up period, study patients had been followed for a median of 252 days (range 12–451 days). Twenty-two patients
(29%) had died, and 52 patients (68%) were alive and in treatment. In patients who did not die, culture conversion was
documented in 52/54 patients (96%). One patient had defaulted, and one patient had transferred out. Death occurred after
a median of 66 days in treatment (range 12–374 days).
Conclusions/Significance: In a region where clinicians and program managers are increasingly confronted by drug-resistant
tuberculosis, this report provides sobering evidence of the difficulty of MDR-TB treatment in high HIV-prevalence settings. In
Lesotho, an innovative community-based treatment model that involved social and nutritional support, twice-daily directly
observed treatment and early empiric use of second-line TB drugs was successful in reducing mortality of MDR-TB patients.
Further research is urgently needed to improve MDR-TB treatment outcomes in high HIV-prevalence settings.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB), defined as resis-
tance to both isoniazid and rifampicin, is a growing problem in
resource-poor settings where adequate diagnosis and treatment are
often unavailable. Sub-Saharan Africa would seem to have all of
the conditions for a ‘‘perfect storm’’ of HIV infection and MDR-
TB [1]. In the most recent World Health Organization (WHO)
report on anti-tuberculosis drug resistance, data were noticeably
absent from African countries, which often do not have the
resources to perform regular drug resistance surveillance [2].
Nevertheless, there is ample evidence that MDR-TB is a major
problem in Africa. In 2006, extensively drug-resistant tuberculosis
(XDR-TB), defined as MDR plus resistance to fluoroquinolones
and second-line injectable drugs, was found in South Africa. It
spread rapidly among HIV immunocompromised patients and
was associated with extremely high mortality [3]. The WHO
reported that, even in the absence of a nationwide survey, South
Africa identified 17,615 MDR-TB isolates over a 4-year period,
996 (5.6%) of which were XDR-TB [2].
Treatment of MDR- and XDR-TB is difficult even in resource-
rich settings. Patients are generally treated for a minimum of
18–24 months with second-line TB drugs that have significant
adverse effects [4]. Most studies of MDR-TB treatment have come
from countries where HIV co-infection is uncommon [5,6]. Thus,
little is known about outcomes of MDR-TB treatment in high
HIV-prevalence settings such as sub-Saharan Africa.
Lesotho is a mountainous nation that is home to two million
people and completely surrounded by the Republic of South
Africa. With respect to HIV and TB, Lesotho is very similar to its
neighbor, South Africa, whereas its medical infrastructure and
resources reflect its significantly lower per capita GDP. It has one
of the highest burdens of HIV infection in the world, with a
prevalence of 23.2% [7]. The prevalence of TB is estimated to be
513 cases per 100,000 population [8]. An estimated 80% of all TB
patients are co-infected with HIV [9]. Accurate data on drug
resistance are currently unavailable, pending the results of a
nationwide drug resistance survey that was started in 2008.
The Lesotho Ministry of Health and Social Welfare recently
began a national treatment program as part of a comprehensive
response to MDR- and XDR-TB. International collaborators
included Partners In Health, the Open Society Institute, the
Foundation for Innovative New Diagnostics (FIND), and the
World Health Organization. Through this program, quality-
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Committee Initiative (GLC) [10] were available to patients
diagnosed with MDR-TB.
We conducted a retrospective analysis of early outcomes of
MDR-TB treatment in the first cohort of patients treated in this
program. To our knowledge, this is the first analysis of MDR-TB
treatment outcomes in the midst of a generalized HIV epidemic in
a resource-poor setting. It is also the first report of a community-
based MDR-TB treatment model in sub-Saharan Africa.
Methods
We retrospectively examined the medical records of consecutive
patients registered by the Lesotho national MDR-TB program
between July 21, 2007 and April 21, 2008. This included all
patients starting treatment with second-line TB drugs for
confirmed or presumptive MDR-TB.
Ethics
As this was a retrospective study of medical information
previously collected in the course of routine clinical care, informed
consent was not required. This study was approved by the Human
Subjects Committee of the Harvard School of Public Health.
Bacteriology and drug susceptibility testing
At the beginning of the study period, the Lesotho National
Reference TB Laboratory performed direct smear microscopy
without fluorescence, but not culture or drug susceptibility testing
(DST). Some patients brought DST results from various public
and private sector TB laboratories in South Africa showing
resistance to isoniazid and rifampicin. These patients were
immediately started on treatment with second-line TB drugs,
and were asked to produce sputum for culture and DST before
starting treatment. Sputum was sent to the Medical Research
Council (MRC) Tuberculosis Laboratory, a supranational refer-
ence laboratory in Pretoria, South Africa for first- and second-line
DST.
Starting in 2007, the Lesotho National Reference TB
Laboratory began receiving training from FIND in culture and
DST. Culture was performed initially on Lo ¨wenstein-Jensen
medium, and later using a BACTEC MGIT 960 system
(Becton-Dickson, Sparks, Maryland, USA). DST was performed
to the first-line drugs of isoniazid, rifampicin, ethambutol and
streptomycin. MDR isolates continued to be sent to MRC for
DST to pyrazinamide and second-line drugs throughout the entire
study period.
Treatment
In general, patients were referred to the Lesotho national MDR-
TB program for evaluation of confirmed or suspected MDR-TB.
Most patients were referred by clinicians working in the Ministry of
Health and Social Welfare network of hospitals and health centers,
but some were referred by private physicians or South African
mining companies. Patients with suspected MDR-TB but without
DST results were categorized according to clinical and bacterio-
logical criteria, and high-risk patients were started empirically on
second-line TB drugs. High-risk categories included: household
contacts of known MDR-TB patients; probable treatment failure of
a WHO Category 1 or Category 2 regimen (defined as smear-
positive in month 5, or HIV-positive and clinical deterioration at
any point during treatment); and history of treatment with second-
line TB drugs (full protocol shown in Table 1).
Treatment protocols followed WHO international guidelines
[11]. A standardized treatment regimen was used for empiric
treatment in patients who had previously received only first-line TB
drugs. The standardized regimen included six drugs—pyrazin-
amide, kanamycin, ofloxacin, ethionamide, cycloserine and para-
aminosalicylic acid. In patients who had previously taken second-
line TB drugs, empiric treatment regimens were designed wherever
possible to avoid drugs that had been taken previously. When
second-line DST results were available, the treatment regimens
were modified accordingly, with the goal of at least five drugs to
which isolates were susceptible. All TB drugs were dosed according
to weight.Dosingand drugs were also changed inresponse to severe
adverse effects. In order to monitortreatment,sputumsampleswere
taken monthly for smear microscopy and culture.
HIV testing was routinely offered at the first consultation to
patients who did not know their HIV serostatus. HIV-positive
patients who were not already taking antiretroviral therapy (ART)
were started on ART as soon as they were tolerating second-line TB
drugs, irrespective of CD4 cell count. ART regimens commonly
consisted of two nucleoside reverse transcriptase inhibitors (zidovu-
dine or stavudine plus lamivudine), and one non-nucleoside reverse
transcriptase inhibitor (efavirenz or nevirapine).
Patients in stable clinical condition were started on MDR-TB
treatment on an ambulatory basis. Patients were evaluated at least
monthly by a trained clinician. All doses of second-line TB drugs
and ARV’s were administered under twice-daily directly observed
treatment (DOT). Community health workers were trained to
provide DOT, monitor for adverse effects and provide psychoso-
cial support. Patients received daily injections from health centre
nurses or by community health workers if living in remote areas.
Patients who were unable to ambulate or were otherwise unstable
Table 1. Protocol for empiric treatment of MDR-TB suspects.
Risk level Category Action
Medium risk Migrant worker with new TB Send two sputums for culture and DST. Start Category 1 regimen.
Medium risk Health worker with new TB Send two sputums for culture and DST. Start Category 1 regimen.
Medium risk Treatment after relapse or default Send two sputums for culture and DST. Start Category 2 regimen.
High risk Household contact of known MDR-TB patient with new TB Send two sputums for culture and DST. Start individualized Category 4
regimen based on DST of contact.
High risk Probable treatment failure:
N Smear-positive in fifth month of Category 1 or 2, or
N HIV-positive and clinically worsening during Category 1 or 2
Send two sputums for culture and DST. Start standardized Category 4
regimen. There are many reasons for clinical worsening in HIV-positive
patients besides treatment failure. Consult specialist for advice.
High risk History of treatment with second-line drugs Send two sputums for culture and DST. Will need an individualized
Category 4 regimen. Consult specialist for advice.
doi:10.1371/journal.pone.0007186.t001
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inpatient facility in the capital (Botsabelo Hospital). Patients were
also admitted if they experienced severe adverse effects or other
clinical complications that could not be managed as outpatients.
All treatment was free of charge. Patients received a monthly food
package and were reimbursed for treatment-related travel
expenses. Community health workers were reimbursed for travel
expenses and were provided with a monthly cash incentive.
Data collection and analysis
Variables collected through a standardized chart abstraction
included: demographic characteristics; previous TB treatment
exposure; previous exposure to antiretroviral therapy; HIV
serostatus; cavitary and bilateral disease on chest radiography;
results of drug susceptibility testing; results of hemoglobin,
creatinine, and hepatic function tests at baseline and during
treatment, and occurrence of serious adverse effects and clinical
complications (definitions shown in Table 2).
Patient follow-up ended when an outcome was recorded, or on
October 21, 2008 for those still on treatment. Possible outcomes
included: death; default (greater than one month of missed doses);
transfer out (transfer with records to another MDR-TB treatment
program); and alive and in treatment. Autopsy was not available;
cause of death was determined after a detailed review of clinical
records and was a consensus decision of the first and last authors.
Univariate analyses (x
2 test) were performed to determine the
associations between clinical characteristics and outcome. Multiple
logistic regression analysis was performed to look for potential
confounders or effect modifiers. SAS software (version 9.1, Cary
Institute, North Carolina, USA) was used for all analysis.
Results
Between July 21, 2007 and April 21, 2008, 81 patients started
treatment with second-line TB drugs for presumptive MDR-TB.
Three patients were subsequently found to be infected with pan-
susceptible M. tuberculosis strains, and two patients were subse-
quently found to be infected with polyresistant, non-MDR strains.
These five patients were excluded from analysis. Baseline
characteristics of the remaining 76 patients are shown in Table 3.
Seventy patients (92%) were sputum AFB-positive before
starting treatment. Of the remainder, five patients were smear-
and culture-negative, including three children; the final patient
was smear-negative but culture-positive. Twenty-nine patients
(38%) were started on treatment with second-line TB drugs
already having laboratory confirmation of resistance to isoniazid
and rifampicin, mostly from South African laboratories. Forty-
seven patients (62%) were started on empiric treatment with
second-line TB drugs without having laboratory-confirmed MDR-
TB. All patients starting empiric MDR-TB treatment had sputum
samples sent for culture and DST, and 26 of these patients
eventually proved to have MDR-TB; the remaining 21 patients
had negative or contaminated cultures. Ten MDR isolates were
tested by MRC in South Africa for resistance to second-line drugs.
Of these, four isolates were found to be resistant to second-line
drugs; one isolate met criteria for XDR-TB.
Only two patients had never been treated for TB. Seventy-four
patients (97%) had previously received TB treatment, ranging
from one to five previous courses of TB treatment (Table 4).Usually
this was with repeated treatments with first-line drugs, but 12
Table 2. Definition of serious adverse effects and clinical complications during MDR-TB treatment.
Pneumothorax Pneumothorax visible on chest radiograph and requiring chest tube placement
Hematemesis Episode seen and documented by any health care worker
Otoxicity Symptomatic hearing loss while receiving injectable drug
Renal insufficiency Elevated creatinine requiring suspension or dose reduction of injectable drug
Severe nausea and vomiting Nausea and vomiting requiring intravenous fluid repletion
Depression Depression treated with anti-depressants and documented by a physician
Seizures Episode of seizures documented by a physician
Psychosis Symptoms treated with anti-psychotics and documented in the clinical record to be due to cycloserine by a physician
Neuropathy Chronic tingling, numbness or pain in the extremities requiring change in ART or TB treatment regimen or treatment with amitriptyline
Severe anemia Hemoglobin ,8 g/dL
Hypokalemia Serum potassium ,3.0 mmol/L
doi:10.1371/journal.pone.0007186.t002
Table 3. Baseline characteristics of MDR-TB patients in
Lesotho.
N (%) Median (range)
Demographics
Female 36 (47.4%)
Age 35.0 (3 – 62)
Months since first diagnosis of TB 16.9 (0 – 316.7)
Clinical
HIV seropositive 56 (73.7%)
Body mass index 17.5 (11.9 – 26.8)
Serum albumin (g/L) 31.3 (13 – 48)
Hemoglobin (g/dL) 11.3 (6.1 – 16.5)
Bilateral disease on CXR
{ 32 (46.4%)
Cavitary disease on CXR
{ 33 (47.8%)
Previous treatment
Number of previous treatment regimens 2 (0 – 5)
Treatment with second-line drugs 6 (15%)
Previous treatment in South Africa 8 (20%)
Household contacts
Number of household contacts 4.0 (0 – 11)
{Out of 69 patients who had a CXR dated within 90 days before or after the
initiation date of second-line TB drugs.
doi:10.1371/journal.pone.0007186.t003
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drugs, usually in South Africa.
Fifty-six patients (74%) were infected with HIV; of the 32
patients who were tested within 90 days before or after initiation of
MDR-TB treatment, the median CD4 cell count was 184 cells/ml
(range 5–824 cells/ml). Of the HIV-positive patients, 24 patients
were already receiving ART, a mean of 369 days (range 13 days to
more than 3 years) before initiation of MDR-TB treatment.
Twenty-five patients were started on ART, a mean of 35 days
(range 11–117 days) after starting MDR-TB treatment. Of the
remaining seven patients, six patients died without starting ART,
and one was alive, in treatment and culture-negative at the end of
the follow-up period.
Fifty-eight patients (76%) experienced at least one hospital-
ization during the follow-up period. Hospitalization ranged
from 2 to 188 days, and the mean length of stay was 33 days.
Seventy patients (92%) experienced at least one serious adverse
effect or clinical complication during the follow-up period
(Figure 1).
By October 21, 2008, study patients had been followed for a
median of 252 days (range 12–451 days). Twenty-two patients
(29%) had died, and 52 patients (68%) were alive and in treatment.
One patient had defaulted, and one patient had moved to South
Africa after culture conversion and was continuing to receive
treatment at another institution. In patients who did not die,
culture conversion—defined as two consecutive negative cultures
greater than 30 days apart [12]—was documented in 52/54
patients (96%). Death occurred after a median of 66 days in
treatment (range 12–374 days). Survival curves stratified by HIV
status are shown in Figure 2. There appeared to be a non-
significant trend towards earlier death for patients who were HIV-
positive (dotted line). The causes of death for the 22 patients who
died are listed in Table 5.
In univariate analyses, hemoglobin ,10 g/dL, serum albumin
,30 g/L, and an age .40 were associated with death (Table 6).
In multiple logistic regression analysis, there was a suggestion of
confounding or interaction between all three of these covariates,
but the sample size precluded definitive conclusions.
Discussion
While there have been many previous studies of MDR-TB
treatment outcomes in resource-poor settings, none have included
significant numbers of HIV-positive patients [13]. In MDR-TB
treatment programs with largely HIV-negative patients, cure rates
Table 4. Previous TB treatment history of MDR-TB patients in
Lesotho.
Number of previous TB treatments N (%)
Zero 2 (3%)
One 24 (32%)
Two 35 (46%)
Three 11 (14%)
Four 3 (4%)
Five 1 (1%)
doi:10.1371/journal.pone.0007186.t004
Figure 1. Major adverse effects and clinical complications during MDR-TB treatment. Adverse effects and clinical complications were
defined as in Table 2. Percentages were calculated out of a total of 76 patients.
doi:10.1371/journal.pone.0007186.g001
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19% [5,6,14,15]. The early results of treatment in Lesotho,
however, indicate that MDR-TB treatment outcomes in HIV-
positive patients are likely to be significantly worse compared to
HIV-negative patients. There was a trend towards poorer
outcomes in HIV-positive patients, with significant mortality in
the first few weeks after initiation. These results are consistent with
previous studies showing increased mortality in HIV-positive
compared to HIV-negative patients with drug-susceptible TB
[16,17]. A high rate of HIV co-infection is one of the major
reasons for the high mortality rate among drug-susceptible TB
patients in sub-Saharan Africa. Harries et al. reported a 23%
death rate among a large cohort of TB patients in Malawi [18].
Alvarez et al. reported a 26.5% death rate among patients with
confirmed pulmonary TB admitted to a South African hospital,
with a median time of death of 25 days [19].
The high early mortality seen in this cohort argues strongly for
early initiation of second-line TB drugs in MDR-TB patients. One
common theme in prior studies of HIV-positive patients with
MDR-TB is the rapidity of death in the absence of effective
treatment. Several studies in the 1980s and 1990s of MDR-TB in
HIV co-infected patients from Europe and the United States
reported mortality rates exceeding 70%, often within 4–8 weeks of
diagnosis, and before laboratory confirmation of MDR-TB [1].
These reports were from the pre-ART era, not that different from
today’s situation in many parts of Africa, where access to ART is
still limited. In a 2006 report from the KwaZulu-Natal province of
Figure 2. Time to death during MDR-TB treatment by HIV status. This figure shows Kaplan-Meier probabilities of survival in HIV-negative
(solid line) and HIV-positive (dotted line) patients. Survival is measured in days after starting MDR-TB treatment. Crosses indicate patients who did not
die by the end of the follow-up period.
doi:10.1371/journal.pone.0007186.g002
Table 5. Cause of death of patients who died during MDR-TB
treatment.
Cause of death Number
Unknown 10
Multiorgan system failure (disseminated TB) 3
Massive upper gastrointestinal hemorrhage 3
Meningitis, unknown etiology 2
Progressive respiratory failure 1
Severe COPD exacerbation 1
Injectable-related renal failure 1
Pneumothorax 1
Total 22
doi:10.1371/journal.pone.0007186.t005
Table 6. Covariates associated with risk of death during MDR-
TB treatment
Covariates OR 95% CI p-value (x
2)
Male gender 2.5 0.9 – 7.1 0.08
HIV seropositive 1.9 0.6 – 6.5 0.30
Baseline albumin ,30 g/L 3.9 1.3 – 11.6 0.01
Baseline hemoglobin ,10 g/dL 3.3 1.2 – 9.4 0.02
Cavitary disease 0.5 0.2 – 1.3 0.19
Bilateral disease 1.2 0.4 – 3.3 0.80
Age .40 2.9 1.0 – 8.0 0.04
BMI ,18.4 2.2 0.8 – 6.3 0.09
Number of previous treatments .=3 1.9 0.6 – 6.1 0.29
Laboratory-confirmed MDR-TB 1.0 0.3 – 3.1 0.96
doi:10.1371/journal.pone.0007186.t006
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median of 16 days from the time of diagnosis [3].
Clinicians are often reluctant to start second-line TB drugs
empirically, without laboratory confirmation of resistance to
isoniazid and rifampicin. But in situations where DST is not
easily accessible, the reliance on laboratory diagnosis can become
a bottleneck to life-saving treatment. In this cohort of patients,
most patients were started empirically on second-line drugs,
without waiting for DST results. Almost all of these patients were
sputum smear-positive and would be expected to have positive
cultures. However, for many patients, the cultures ended up being
negative or contaminated, since in the initial phase of the
program, the raw sputum had to be transported over long
distances to a laboratory in South Africa. Even in settings where
there is ready access to culture and DST, empiric MDR-TB
treatment is a strategy that can decrease the time to effective
treatment. The most commonly available DST methods utilize
culture on solid or liquid media, which, at a minimum, require
several weeks or months, ample time for a patient to clinically
worsen or die while receiving ineffective first-line TB drugs. With
the aid of clear guidelines and protocols, clinicians can be trained
to identify patients at high risk for MDR-TB and initiate second-
line TB drugs empirically. There is much to be gained and little to
be lost by a starting a well-designed empiric MDR-TB treatment
regimen in high-risk patients [20,21,22]. If DST subsequently
shows the patient to be infected with drug susceptible TB, the
patient can be simply switched back to a first-line regimen.
In this cohort, the majority of patients (62%) received empiric
MDR-TB treatment, and therefore benefited from effective
therapy earlier than they would have normally. Nevertheless, by
many objective measures, they did not benefit early enough. In
this largely HIV-positive population with advanced immunosup-
pression, a high proportion of smear-negative patients would
normally be expected. In fact, 92% of the patients were smear-
positive. Many of them may have originally had smear-negative
pulmonary TB, but by the time they were referred for suspicion of
MDR-TB, the sputum bacillary load was much higher. Ninety-
seven percent were retreatment cases, with 65% previously
receiving two or more TB treatments. This means that for most
patients, there had previously been multiple missed opportunities
for MDR-TB diagnosis before referral. The most common
pathway to a diagnosis of MDR-TB in resource-poor settings is
through multiple failed treatments with standardized regimens of
first-line TB drugs. This strategy is unlikely to result in acceptable
MDR-TB treatment outcomes in high HIV-prevalence settings,
even in those settings with greater medical resources than Lesotho,
such as South Africa. For the first cohort of MDR-TB patients
treated in Lesotho, where DST and second line TB drugs had
previously been unavailable, this sort of delayed diagnosis may be
understandable, but probably was one of the factors responsible
for the high early mortality. In the future, earlier diagnosis of
MDR-TB, and in particular, increasing the diagnosis of MDR-TB
among new TB patients, as has been done in other countries with
more mature MDR-TB treatment programs [6], will likely be
necessary to improve overall treatment outcomes.
Another major bottleneck to MDR-TB treatment in the
southern Africanregionis a relianceon hospital-based treatment.
In many countries, patients with MDR-TB are routinely
admitted to the hospital for several months at the start of
treatment. This is partly for clinical reasons and partly to protect
the community from infection [23]. Unfortunately, if the number
of MDR-TB cases outstrips the supply of hospital beds, patients
may have to queue for treatment. In certain areas of South
Africa, patients may wait for several months before an MDR-TB
hospital bed opens up [24]. Ironically, this policy likely increases
community transmission of MDR- and XDR-TB strains, since
patients continue to be infectious in the community without
effective treatment. Furthermore, the reliance on hospital-based
MDR-TB treatment also likely increases nosocomial transmis-
sion, since MDR-TB wards in resource-poor settings often have
no additional infection control measures than do general hospital
wards [25].
In Lesotho, a community-based model of MDR-TB treatment
was found to be feasible, as it has been in other countries [14,26].
Community health workers were successfully trained to support
patients, observe doses, provide injections, and monitor for
adverse effects. All outpatients received twice-daily DOT from a
trained community health worker. Only patients requiring a
higher level of care were admitted to the hospital; once they were
medically stable and able to care for themselves with assistance
from family, they were discharged back to community-based care.
This relationship between hospital-based and community-based
staff requires close communication, but maximizes programme
resources for the largest number of patients and provides close
follow-up throughout all stages of treatment. Given the serious
outbreak of MDR-TB in the southern Africa region and the
limited public health response to date, improved hospital facilities
are certainly needed. A strong community-based treatment
programme, however, should be an important aspect of any
national response to MDR-TB.
In Lesotho, the default rate appeared to be quite low compared
to typical default rates of 15–20% among MDR-TB patients in
South Africa [27,28]. One advantage of community-based DOT
over self-administered treatment is closer monitoring of adverse
effects. Adverse effects and other clinical complications occurred
early and often in Lesotho, compared to HIV-negative settings
[29,30,31]. HIV-positive patients are known to have an increased
incidence of adverse effects of first-line TB drugs [32,33,34], and
the incidence of adverse effects of second-line TB drugs may be
increased as well. Some adverse effects, such as seizures and
psychosis, were most likely due to second-line TB drugs (e.g.,
cycloserine). Others, such as peripheral neuropathy, are known
adverse effects of second-line TB drugs, but can also be caused or
exacerbated by other conditions (e.g., HIV peripheral neuropathy)
or other drugs (e.g., stavudine) commonly taken by HIV-positive
patients. We surmise that the increased frequency and rapid onset
of many side effects and clinical complications, such as
hypokalemia, anemia or renal insufficiency, were related to the
poor clinical status and baseline malnutrition prevalent in this
patient population, but further research is needed.
Community health workers also play an important role in
ensuring that patients receive the psychological, social, and
economic support required to complete treatment. Community-
based MDR-TB treatment should include an assessment of the
home situation and nutritional intervention when necessary. In
Lesotho, all patients treated for MDR-TB were provided with a
monthly food package. The high prevalence of low BMI and
hypoalbuminemia in our cohort was probably caused by chronic
malnutrition, not just chronic TB and HIV infection. MDR-TB
patients in this region likely suffer from energy, protein and
micronutrient deficiencies, all of which can contribute to early
mortality, side effects and clinical complications in patients with
TB or HIV [35,36,37].
Limitations
There are several caveats and limitations to this analysis that
should be considered before extrapolating to other patient
populations and programs. This analysis included patients who
MDR-TB/HIV Treatment Outcomes
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protocols strongly promoted empiric treatment of MDR-TB, and
DST was not readily available during the entire study period. The
inclusion of non-MDR strains, furthermore, would not have
affected the results reported here, since according to national
protocol, the standardized MDR-TB treatment regimen did not
include isoniazid or rifampicin. No patients in this cohort
benefited from the superior activity of these drugs, even in the
event that some patients were infected with pan-susceptible TB.
The early outcomes reported here may be different from the final
outcomes; reporting of MDR-TB treatment outcomes generally
requires more than two years of follow-up, in order to fully
account for late death, treatment failure, default, and recurrent
disease [12]. The size of the cohort was too small to do meaningful
multivariable analysis; univariate associations will have to be
reexamined in larger cohorts. Finally, the incidences of some
important adverse effects, most notably hypothyroidism, are not
reported here, because they were not included in the screening
protocol in the beginning of this program.
In a region where clinicians and program managers are
increasingly confronted by MDR- and XDR-TB, this report
provides sobering evidence of the difficulty of MDR-TB treatment
in high HIV-prevalence settings. Nevertheless, in Lesotho, an
innovative community-based treatment model that involved social
and nutritional support, strict DOT, and early empiric use of
second-line TB drugs was successful in reducing mortality of
MDR-TB patients. Further research is urgently needed to improve
MDR-TB treatment outcomes in high HIV-prevalence settings.
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